Literature DB >> 18784265

Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).

Kanako Sakuyama1, Takamitsu Sasaki, Shuta Ujiie, Kanako Obata, Michinao Mizugaki, Masaaki Ishikawa, Masahiro Hiratsuka.   

Abstract

Cytochrome P450 2D6 (CYP2D6) is an enzyme of potential importance for the metabolism of drugs used clinically, and it exhibits genetic polymorphism with interindividual differences in metabolic activity. To date, 21 CYP2D6 allelic variants have been identified in the Japanese population. The aim of this study was to investigate the functional characterization of CYP2D6 variants identified in Japanese subjects. Wild-type CYP2D6 and its variants, namely, CYP2D6.2, CYP2D6.10, CYP2D6.14A, CYP2D6.14B, CYP2D6.18, CYP2D6.27, CYP2D6.36, CYP2D6.39, CYP2D6.47, CYP2D6.48, CYP2D6.49, CYP2D6.50, CYP2D6.51, CYP2D6.53, CYP2D6.54, CYP2D6.55, and CYP2D6.57 were transiently expressed in COS-7 cells, and enzymatic activities of the CYP2D6 variant proteins were characterized using bufuralol and dextromethorphan. Functional characterization of 17 CYP2D6 variants revealed an absence of enzyme activity in four (CYP2D6.14A, CYP2D6.36, CYP2D6.47, and CYP2D6.57), low activity in eight (CYP2D6.10, CYP2D6.14B, CYP2D6.18, CYP2D6.49, CYP2D6.50, CYP2D6.51, CYP2D6.54, and CYP2D6.55), and high activity in one (CYP2D6.53) compared with the wild type. Analysis of CYP2D6 variant proteins can be useful for predicting CYP2D6 phenotypes and could be applied to personalized drug therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784265     DOI: 10.1124/dmd.108.023242

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  39 in total

1.  Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population.

Authors:  Kazuma Kiyotani; Makiko Shimizu; Toshio Kumai; Tetsuya Kamataki; Shinichi Kobayashi; Hiroshi Yamazaki
Journal:  Eur J Clin Pharmacol       Date:  2010-08-11       Impact factor: 2.953

2.  The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.

Authors:  Junichi Azuma; Tomoko Hasunuma; Masanori Kubo; Masaya Miyatake; Toshiko Koue; Koushi Higashi; Tsutomu Fujiwara; Sachiko Kitahara; Tamiki Katano; Sumiko Hara
Journal:  Eur J Clin Pharmacol       Date:  2011-07-08       Impact factor: 2.953

3.  Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.

Authors:  Amelia Nathania Dong; Nafees Ahemad; Yan Pan; Uma Devi Palanisamy; Beow Chin Yiap; Chin Eng Ong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-26       Impact factor: 3.000

4.  CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.

Authors:  Rajiv Balyan; Marc Mecoli; Raja Venkatasubramanian; Vidya Chidambaran; Nichole Kamos; Smokey Clay; David L Moore; Jagroop Mavi; Chris D Glover; Peter Szmuk; Alexander Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2017-02-17       Impact factor: 2.533

5.  CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712.

Authors:  Sarah M Glass; Cydney M Martell; Alexandria K Oswalt; Victoria Osorio-Vasquez; Christi Cho; Michael J Hicks; Jacqueline M Mills; Rina Fujiwara; Michael J Glista; Sharat S Kamath; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2018-05-21       Impact factor: 3.922

6.  CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels.

Authors:  Balmiki Ray; Eren Ozcagli; Wolfgang Sadee; Danxin Wang
Journal:  Pharmacogenet Genomics       Date:  2019-02       Impact factor: 2.089

7.  Pinoline may be used as a probe for CYP2D6 activity.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2008-12-18       Impact factor: 3.922

Review 8.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity.

Authors:  Danxin Wang; Ming J Poi; Xiaochun Sun; Andrea Gaedigk; J Steven Leeder; Wolfgang Sadee
Journal:  Hum Mol Genet       Date:  2013-08-28       Impact factor: 6.150

10.  Variability in Human In Vitro Enzyme Kinetics.

Authors:  Christopher R Gibson; Ying-Hong Wang; Ninad Varkhede; Bennett Ma
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.